Fig. 3From: Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy)Confirmed tumor response on whole body 18F-FDG PET/CT MIP images obtained in a66 year old male stage IV-M1c melanoma patient with a BRAF N486_P590del (in-frame deletion, class II BRAF mutation) treated with trametinib 2 mg QD plus dabrafenib 50 mg BIDBack to article page